United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 781.50M | 790.20M | 799.50M | 798.60M | 794.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 781.50M | 790.20M | 799.50M | 798.60M | 794.40M |
| Cost of Revenue | 133.40M | 103.40M | 100.90M | 87.60M | 92.50M |
| Gross Profit | 648.10M | 686.80M | 698.60M | 711.00M | 701.90M |
| SG&A Expenses | 184.10M | 189.90M | 181.80M | 190.80M | 170.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 455.70M | 432.80M | 410.20M | 412.40M | 411.60M |
| Operating Income | 325.80M | 357.40M | 389.30M | 386.20M | 382.80M |
| Income Before Tax | 318.30M | 444.00M | 438.00M | 408.40M | 423.50M |
| Income Tax Expenses | 43.40M | 79.70M | 99.30M | 98.90M | 101.30M |
| Earnings from Continuing Operations | 274.90M | 364.30M | 338.70M | 309.50M | 322.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 274.90M | 364.30M | 338.70M | 309.50M | 322.20M |
| EBIT | 325.80M | 357.40M | 389.30M | 386.20M | 382.80M |
| EBITDA | 348.40M | 380.20M | 411.20M | 407.30M | 402.60M |
| EPS Basic | 6.32 | 8.41 | 7.73 | 6.86 | 7.18 |
| Normalized Basic EPS | 5.46 | 5.75 | 6.18 | 6.02 | 5.97 |
| EPS Diluted | 5.82 | 7.70 | 7.16 | 6.41 | 6.63 |
| Normalized Diluted EPS | 5.03 | 5.26 | 5.72 | 5.62 | 5.51 |
| Average Basic Shares Outstanding | 43.50M | 43.30M | 43.80M | 45.10M | 44.90M |
| Average Diluted Shares Outstanding | 47.20M | 47.30M | 47.30M | 48.30M | 48.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |